Press Releases Items Per Page 102550 Year None2021202020192018201720162015201420132012201120102007 04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting 03.27.19 Syndax Announces $26.2 Million Offering of Common Stock and Warrants 03.07.19 Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update 03.06.19 Syndax to Present at the Cowen 39th Annual Health Care Conference 02.28.19 Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019 02.27.19 Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019 01.07.19 Syndax Highlights 2019 Clinical and Corporate Outlook 12.03.18 Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting 11.05.18 Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update 11.01.18 Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting 10.29.18 Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018 10.25.18 Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer Pagination First page « first Previous page ‹ previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page next › Last page last »
04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting
03.07.19 Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
02.28.19 Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
02.27.19 Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019
12.03.18 Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting
11.05.18 Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
11.01.18 Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting
10.29.18 Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018
10.25.18 Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer
